Colorcon acquires NP Pharm

NewsGuard 100/100 Score

Colorcon, Inc. today announced the acquisition of the full-service pharmaceutical excipient company, NP Pharm, a Division of Ethypharm.  This acquisition expands Colorcon's global excipient product offerings in the pharmaceutical and nutritional markets.

The addition of NP Pharm SUGLETS® sugar spheres complements Colorcon's SureSpheres® sugar spheres product line and barrier membrane systems for multiparticulates.  Colorcon will now have two production facilities for sugar spheres offering critical business continuity planning for their customer base.  ETHISPHERES® microcrystalline cellulose pellets, NPTAB® neutral pellets for direct compression, and other excipient products are also added to the Colorcon product portfolio as a result of this acquisition.

The headquarters and main production facilities of NP Pharm, located in Bazainville, France, will become an integral part of the Colorcon network of manufacturing sites.

William Motzer, Colorcon Chief Executive Officer states, "We are excited about this opportunity to expand Colorcon's product offerings and leverage our global distribution, technical service and sales infrastructure."

Newly appointed Chairman and CEO of the Management Board of Ethypharm, Hugues Lecat states, "We are delighted to see NP Pharm join Colorcon, Inc.  The new shareholder will permit NP Pharm to reinforce its development and growth projects.  This divestiture will enable us to go on investing in the growth of Ethypharm, in line with our strategy.  Ethypharm will continue to invest in its R&D sites, notably that of Grand Quevilly, France, our most recent state-of-the-art manufacturing plant, in which we have invested over 15 million Euros over the last two years."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles